MO-BLUE-YONDER
24.1.2023 14:02:00 CET | Business Wire | Press release
To improve customer experience and satisfaction, retailers are looking to offer a personalized assortment and easy to navigate display of products in their stores. That’s why Nestlé Purina Petcare, the leading manufacturer of pet care products, has successfully implemented Blue Yonder’s category management solution integrated with 3DVR Solutions’ (3DVRS) 3D virtual reality technology to assist its retail partners with better merchandizing of their store shelfs.
Purina is the No. 1 pet care company in the U.S. It offers more than 20 brands in the U.S., feeding 65 million dogs and 51 million cats annually. Purina provides its retail partners with planograms that design shelfs aimed at merchandizing products to meet customer needs. However, with travel restricted during the COVID-19 lockdowns, it needed an alternate way for its associates to work with its retail partners remotely to replicate critical tasks that would otherwise be performed in front of a physical planogram or in store.
Enter 3DVRS’ innovative Retail Visualisation Suite (RVS) Virtual Reality (VR) Headset solution, which combines planogram data from Blue Yonder with a cutting-edge virtual reality headset provider to deliver a fully interactive, networked avatar-based merchandising solution. This integrated solution brings people from all over the globe into a common unique headset experience in the metaverse where they can plan, present and interact. The integrated solution is now also available to other companies who are looking to solve similar challenges.
Thanks to this integrated solution, Purina has achieved some key benefits:
- Removed the need to be in a physical store to make shelfing decisions by bringing people together in the metaverse, which has in turn reduced environmental impact from less travel and decreased training costs.
- Reduced time to merchandise a shelf via an interactive planogram before moving real product.
- Incorporated true-to-life factors into shelf planning.
- Partner with retailers to enhance the customer journey in store and share global best practices.
“3DVRS’ integration with Blue Yonder delivers flexibility, speed and scale, giving us the ability to effectively deploy across the business. The evolution from virtual reality on the desktop to network avatars in the RVS VR Headset solution has been seamless. We can now hold meetings virtually in the metaverse, interact with layouts, products, and store innovations, allowing us to be right at the cutting edge,” said Gene Feldman, training manager, Purina.
Together, Blue Yonder's category management and 3DVRS’ RVS VR Headset solutions have enabled Purina’s retail partners to make faster, more accurate and localized space allocation decisions to help their customers find the products they need more easily while guaranteeing a better shopping and service experience.
“Purina is a fantastic partner to innovate with as they are always looking to the latest technology to give their business the edge. The challenges they presented pushed technological boundaries. Our integration with Blue Yonder gives us the platform to support large enterprises such as Purina. It’s great to bring new tech to the market that makes a real difference. It’s amazing what we have achieved together already, but I sense there's a lot more to come,” said Nigel Hemer, CEO and founder, 3DVR Solutions.
“Working with 3DVRS has allowed us to bring Blue Yonder’s planograms to life in the metaverse where users can merchandise, analyze, interact, and meet as avatars to design shelfs that meet customers’ needs. This is cutting-edge technology at its finest and Purina was one of the first companies to benefit from it. By creating a culture of innovation and thought leadership throughout the organization, Purina is building a great place to work for both their associates and retail partners,” said Phillip Teschemacher, corporate vice president, Manufacturing - EMEA, Blue Yonder.
Additional Resources:
- Learn more about Blue Yonder's category management solution
- Learn how to achieve smarter Category Management with Blue Yonder
About Nestlé Purina PetCare
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations.
Purina manufactures some of the world's most trusted and popular pet care products, including Purina Cat Chow, Purina ONE, Pro Plan, Fancy Feast and Tidy Cats. Our more than 8,700 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 51 million dogs and 65 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition. Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations.
Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive. Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
About 3DVR Solutions
As a global Blue Yonder technology partner for 10 years, 3DVRS leverages Blue Yonder planogram and store CAD data to create highly visual 3D environments, enabling retailers & suppliers to plan, design and respond to rapidly changing market conditions. The unique design of 3DVR’s virtual reality solutions deliver automation, speed and scale without inherent dependencies and costs. 3DVR support Blue Yonder customers around the globe, including those on Microsoft Azure. www.3dvrs.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformations and omni-channel commerce fulfillment. Our end-to-end, cognitive business platform enables retailers, manufacturers and logistics providers to best fulfill customer demand from planning through delivery. With Blue Yonder, you'll unify your data, supply chain and retail commerce operations to unlock new business opportunities and drive automation, control and orchestration to enable more profitable, sustainable business decisions. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005378/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom